Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS) GlobeNewswire July 09, 2025 Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating […]

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) GlobeNewswire July 09, 2025 GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has

Bitdeer Announces June 2025 Production and Operations Update GlobeNewswire July 09, 2025 – Joined the Russell 2000(R) and 3000(R) Indexes as of June 30, 2025– SEALMINER A3 series almost ready for mass production– Increased self-mining hashrate by 21% to 16.5 EH/s on continued deployment of SEALMINERs SINGAPORE, July 09, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference GlobeNewswire July 09, 2025 WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will

Class 1 Nickel Commences 2025 Exploration Program at the River Valley PGE-Cu-Ni Project, Ontario, Canada GlobeNewswire July 09, 2025 TORONTO, July 09, 2025 (GLOBE NEWSWIRE) — Class 1 Nickel and Technologies Limited (CSE: NICO | OTCQB: NICLF) (“Class 1” or the “Company”) is pleased to announce the launch of its 2025 summer exploration program on

Amerigo Reports Q2-2025 Operational Results GlobeNewswire July 09, 2025 Q2-2025 copper production of 15.5 million pounds 2025 production and cash cost1 guidance remain in place $7.6 million returned through Share Buybacks and Dividends in Q2-2025 VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is

NextGen Digital Announces Private Placement of Special Warrants Convertible into Secured Digital Asset-Backed Notes NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES GlobeNewswire July 09, 2025 Vancouver, B.C., July 09, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company“) is pleased to

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) GlobeNewswire July 09, 2025 REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease

Theratechnologies Reports Financial Results for the Second Quarter 2025 GlobeNewswire July 09, 2025 Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025 Positive Adjusted EBITDA1 for the fifth straight quarter Subsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study GlobeNewswire July 09, 2025 [IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell's Bria-OTS in Phase 1/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, British